Lataz-Co

Timolol maleate and latanoprost, the active ingredients in Lataz-Co, are a beta‑blocker and prostaglandin analog presented as eye drops for ocular use. They reduce intra‑ocular pressure in adults with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Lataz-Co as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lataz-Co combines a beta‑blocker and a prostaglandin analog to manage intra‑ocular pressure in glaucoma and related conditions.

Open‑angle glaucoma: lowers intra‑ocular pressure to help prevent optic nerve damage. Ocular hypertension: reduces elevated eye pressure to lower the risk of developing glaucoma. Post‑surgical pressure control: assists in maintaining target pressure after glaucoma surgery.

Lataz-Co may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye irritation or burning sensation - Blurred vision - Redness of the eye - Itching or mild allergic reaction - Dry eye or foreign‑body sensation - Temporary changes in eyelash growth

Serious or Rare Side Effects: - Severe allergic reaction (e.g., swelling, rash, difficulty breathing) - Exacerbation of asthma or chronic obstructive pulmonary disease - Marked bradycardia or hypotension - Uveitis or intra‑ocular inflammation - Corneal edema or keratitis - Persistent visual disturbances

Before using Lataz-Co, consider the following safety measures.

Assess cardiovascular status: avoid in patients with severe bradycardia or heart block. Monitor respiratory conditions: use cautiously in individuals with asthma or COPD. Check ocular surface health: may worsen dry eye or existing corneal disease. Avoid concurrent miotics: combined use can increase risk of ocular side effects. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at room temperature below 25°C: keep in original pack, protect from light and moisture.

Lataz-Co can interact with several systemic and ocular medications.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers (e.g., propranolol): additive cardiovascular depression. - Other prostaglandin analog eye drops: increased risk of ocular irritation. - Topical adrenergic agonists (e.g., epinephrine): may diminish IOP‑lowering effect.

Moderate Interactions (Monitor Closely):\n- Carbonic anhydrase inhibitors (e.g., dorzolamide): additive intra‑ocular pressure reduction. - Topical anesthetics: heightened corneal toxicity risk. - Systemic antihypertensives: possible additive hypotensive effect.